DRI Healthcare Trust (TSE:DHT.UN) Receives Consensus Rating of “Moderate Buy” from Analysts

DRI Healthcare Trust (TSE:DHT.UN) has earned an average recommendation of “Moderate Buy” from the six analysts that are currently covering the company, Marketbeat reports. One investment analyst has rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average 12 month target price among analysts that have updated their coverage on the stock in the last year is C$18.00.

Several equities research analysts have weighed in on the company. Scotiabank boosted their price objective on DRI Healthcare Trust from C$21.00 to C$22.00 and gave the stock an “outperform” rating in a research note on Tuesday, October 8th. Raymond James dropped their target price on DRI Healthcare Trust from C$23.00 to C$22.00 in a report on Wednesday, November 13th.

DRI Healthcare Trust Price Performance

Shares of DRI Healthcare Trust stock opened at C$8.70 on Thursday. The stock has a 50 day moving average of C$13.39 and a 200 day moving average of C$13.40. DRI Healthcare Trust has a 12 month low of C$10.39 and a 12 month high of C$17.43.

DRI Healthcare Trust Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Friday, October 18th. Stockholders of record on Friday, October 18th were paid a dividend of $0.085 per share. The ex-dividend date was Friday, September 27th. This represents a $0.34 dividend on an annualized basis and a dividend yield of 3.91%. DRI Healthcare Trust’s dividend payout ratio is presently -920.00%.

DRI Healthcare Trust Company Profile

DRI Healthcare Trust focuses on managing and growing a portfolio of pharmaceutical royalties. It owns a portfolio of 18 royalties derived from the sale of 14 various pharmaceutical products that focuses on eight therapeutic areas. The company was incorporated in 2020 and is headquartered in Toronto, Canada.